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Abstract
Objective. To compare the carotid intimamedia thickness (IMT) assessed with automated radiofre-
quency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls.
Methods. Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at
seven centres. Cardiovascular (CV) risk factors and co-morbidities, RA characteristics and therapy were
recorded. Common carotid artery (CCA)-IMT was assessed in RA patients and controls with automated
radiofrequency-based US by the same investigator at each centre.
Results. Forty-five (47.9%) RA patients had been treated with synthetic DMARDs and 49 (52.1%) with
synthetic and biologic DMARDs. There were no significant differences between the RA patients and
controls in demographics, CV co-morbidities and CV disease. There were significantly more smokers
among RA patients treated with synthetic and biologic DMARDs (P= 0.036). Disease duration and duration
of CS and synthetic DMARD therapy was significantly longer in RA patients treated with synthetic and
biologic DMARDs (P<0.0005). The mean CCA-IMT was significantly greater in RA patients treated only
with synthetic DMARDs than in controls [591.4 (98.6) vs 562.1 (85.8); P= 0.035] and in RA patients treated
with synthetic and biologic DMARDs [591.4 (98.6) vs 558.8 (95.3); P= 0.040). There was no significant
difference between the mean CCA-IMT in RA patients treated with synthetic and biologic DMARDs and
controls (P= 0.997).
Conclusion. Our results suggest that radiofrequency-based measurement of CCA-IMT can discriminate
between RA patients treated with synthetic DMARDs vs RA patients treated with synthetic and biologic
DMARDs.
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Introduction
There is a body of evidence that supports the pathogenic
role of chronic inflammation in atherosclerosis [15].
This condition and its consequent cardiovascular (CV)
events are largely responsible for the increased morbidity
and mortality risk in RA patients [610].
Intimamedia thickness (IMT) of the common carotid
artery (CCA) measured by B-mode US is increasingly
used as a valid non-invasive surrogate marker of athero-
sclerosis and an end point of CV disease, independent of
traditional CV risk factors, in observational and interven-
tional studies [1114]. In RA patients, increased CCA-IMT
assessed by US has shown independent predictive value
in relation to both subclinical atherosclerosis and CV
events [15, 16].
In different RA populations with early or established dis-
ease, and with and without classical CV risk factors, a
significantly increased CCA-IMT has been demonstrated
as compared with matched controls [5, 1723]. Two sys-
tematic literature reviews and meta-analyses have rein-
forced this evidence [24, 25]. CCA-IMT correlated
positively with disease duration and clinical and laboratory
parameters of inflammatory activity on the one side [17,
18, 2123] and with age and traditional CV risk factors on
the other side [17, 18, 21, 23] in previously published stu-
dies. Some studies have reported that the suppression of
inflammation by biologic therapies (e.g. TNF blocking
agents) has a protective effect against developing athero-
sclerosis and CV events [2630].
In the above literature, the CCA-IMT was measured
online or offline from B-mode images by manual,
semi-manual or automated detection of the lumenintima
and mediaadventitia interfaces over an artery segment
[31]. These methods are highly machine and operator de-
pendent, require substantial specific training, and can be
time consuming. US technology based on radiofrequency
provides an automated method for measuring carotid
IMT, which is uninfluenced by the B-mode image quality
and less dependent on the experience in vascular US of
the examiner [32].
We have previously demonstrated multi-examiner
reproducibility and feasibility of automated radio-
frequency-based CCA-IMT measurement performed by
rheumatologists in RA patients [33]. In addition, the
above method has shown good agreement with the con-
ventional B-mode US measurement of CCA-IMT [3335].
The objective of this multicentre study was to compare
the CCA-IMT measured by automated radiofrequency-
based US in RA patients treated with synthetic vs syn-
thetic and biologic DMARDs and controls.
Methods
Study population
Ninety-four patients with RA according to the ACR 1987
criteria [36], who consecutively attended the outpatient
rheumatology clinics, and 94 sex- and age-matched con-
trols were prospectively recruited at seven centres.
The study was conducted in accordance with the
Declaration of Helsinki and was approved by the local
ethical committee of the involved centres (Hospital
General Universitario Gregorio Maran˜o´n, Spain; Instituto
Poal, Spain; Hospital de Valdecilla, Spain; Hospital
Universitario Infanta Sofı´a, Spain; Hospital Moise`s
Broggi de Sant Joan Despı´, Spain; Hospital Basurto,
Spain; Hospital Clı´nico San Carlos, Spain; Hospital
Universitario Infanta Leonor, Spain). Written informed con-
sent was obtained from all patients before the study.
Clinical and laboratory assessment
The following demographic and clinical data were re-
corded for each RA patient and control at study enrol-
ment: age, sex and history of CV risk factors and
diseases. Each subject was questioned about the follow-
ing co-morbidities and CV risk factors: hypertension, dia-
betes mellitus, dyslipidaemia, renal insufficiency, obesity,
hyperuricaemia or gout, peripheral atherosclerotic arterial
disease, coronary artery disease or events, cerebrovascu-
lar events, family history (i.e. first-grade relatives) of early
(<50 years) CV events, and current or past smoking habit.
These co-morbidities were defined according to pub-
lished criteria [16] (see supplementary data, available at
Rheumatology Online). In addition, the following data were
recorded for RA patients: disease duration and CSs, syn-
thetic and biologic DMARDs received for RA.
RA patients and controls underwent clinical assessment
at study entry that consisted of systolic blood pressure
(SBP) and diastolic blood pressure (DBP), waist circum-
ference (at the level of the cranial edge iliac crest) and
BMI. RA activity was estimated by calculating the DAS
in 28 joints (DAS28) for each RA patient. Functional ability
was evaluated with a self-assessment Spanish version of
the HAQ. ESR (normal 1020 mm/h), CRP (normal
010 mg/l), RF (normal 015 IU/ml) and ACPA (normal
020 U) were also obtained at study enrolment.
Automated radiofrequency-based US measurement
of CCA-IMT
CCA-IMT was assessed in both RA patients and controls
by the same investigator at each centre, blinded to clin-
ical and laboratory data, with seven commercially avail-
able real-time scanners (i.e. five MyLab 25 Gold and two
Mylab 70; Esaote, Genoa, Italy) equipped with 712 MHz
linear transducers and the same automated software-
guided technique, RF-Quality Intima Media Thickness
(QIMT; Esaote, Maastricht, Holland). These investigators
were expert in musculoskeletal (MS) US and had demon-
strated good inter- and intra-observer reliability in measur-
ing CCA-IMT in RA patients [33].
IMT was measured at the posterior wall of the right and
left CCA, 10 mm from the carotid bifurcation over the
proximal 15-mm long segment. The patients were
placed in the supine position with their heads slightly
bent to the opposite direction of the examination side.
The right CCA was first identified in B-mode in a trans-
verse view and followed from the proximal part to the bulb
origin. Immediately after, the CCA and the most proximal
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part of the bulb were imaged in a longitudinal view from a
lateral approach (supplementary Fig. S1, available as sup-
plementary data at Rheumatology Online). The QIMT soft-
ware was enabled by pressing a specific button at the
scanner keyboard. A 15-mm long region of interest (ROI)
and a reference line on the left were superimposed on the
B-mode image. The vertical reference line was placed on
the bulb origin. The distance between this line and the left
margin of the ROI was 10 mm. The ROI was positioned so
that a marker in the middle of the reference line was
located in the centre of the artery lumen. The mean and
S.D. of the IMT values from the last six cardiac cycles were
continuously calculated by the system and displayed on
the left side of the image. According to the manufacturers,
the S.D. should be <20 mm to maximize the quality and
accuracy of the IMT measurements. As soon as the S.D.
was <20mm for the first time during the measurement
process, the investigators froze the image and collected
the mean IMT value for analysis. The QIMT values were
expressed in micrometres (supplementary Fig. S2, avail-
able as supplementary data at Rheumatology Online). This
procedure was repeated on the left CCA.
Statistical analysis
Statistical analysis was performed using SPSS, version
15.0 (SPSS, Chicago, IL, USA). Quantitative variables
were presented as the mean (S.D.) and range or median
and interquartile range (Q1Q3) depending on the normal-
ity assumption checked with the KolmogorovSmirnov
test. Qualitative variables were summarized as absolute
and relative frequencies. T-test or MannWhitney U-test
was used to compare means between two independent
samples depending on the assumptions for parametric
tests, and one-factor analysis of variance (ANOVA) and
post hoc Tukey test or KruskalWallis test and
MannWhitney U-test with Bonferroni correction to com-
pare means between three independent samples.
Pearson’s 2-test and Fisher’s exact test were used to
compare frequencies. Correlations between quantitative
variables were analysed by Pearson’s correlation coeffi-
cient. P<0.05 was considered significant.
Results
Sample characteristics
The studied population comprised 188 subjects,
22 (11.7%) men and 166 (88.3%) women, 94 RA patients
and 94 sex- and age-matched controls. Of the 94 RA pa-
tients, 45 (47.9%) had been treated with synthetic
DMARDs (mainly MTX and LEF) and 49 (52.1%) with syn-
thetic and biologic DMARDs (i.e. adalimumab, infliximab,
etanercept, rituximab, tocilizumab, abatacept, golimu-
mab, ofatumumab); 24 patients had received one biologic
agent, 19 patients had received two biologic agents and
6 patients had received three biologic agents.
Seventy-five (80%) patients had received systemic CSs.
The control group comprised 86 volunteers without
rheumatic diseases and eight patients with non-
inflammatory rheumatic diseases (i.e. FM, two patients;
OA, two patients; rotator cuff tendinopathy, two patients;
osteoporosis, one patient; mechanical dorsalgia, one
patient).
Table 1 displays demographic, clinical and laboratory
data for RA patients who had received only synthetic
DMARDs, RA patients who had received synthetic and
biologic DMARDs and controls. There were no significant
differences between the three groups in demographics,
CV co-morbidities, CV events and family history of CV
disease. There were significantly more smokers among
RA patients treated with synthetic and biologic DMARDs
than among either, RA patients treated only with synthetic
DMARDs or controls (P= 0.036). Disease duration and
duration of CS and synthetic DMARD therapy was signifi-
cantly longer in RA patients treated with synthetic and
biologic DMARDs than in RA patients treated only with
synthetic DMARDs (P< 0.0005). The median HAQ and
the number (percentage) of positive ACPA patients were
also significantly higher in RA patients who had received
synthetic and biologic agents as compared with RA
patients who had received only synthetic DMARDs
(P= 0.029 and P= 0.043, respectively). There were no sig-
nificant differences between both groups in DAS28, RF,
ESR and CRP values.
CCA-IMT in RA patients and controls
CCA-IMT measurements ranged from 349 to 744 mm in
the control group, from 377 to 851 mm in the RA group
treated with synthetic DMARDs and from 300 to 773 mm
in the RA group treated with synthetic and biologic
DMARDs. CCA-IMT correlated significantly with age in
the three groups. These correlations were as follows:
r= 0.51, P< 0.0005 for controls; r= 0.49, P= 0.001 for
RA patients treated with synthetic DMARDs; and
r= 0.72, P< 0.0005 for RA patients treated with synthetic
and biologic DMARDs. Table 2 displays CCA-IMT values
for RA patients and controls. There were significant differ-
ences between the three groups (P= 0.023). Post hoc
Tukey’s pairwise comparisons showed that the mean
CCA-IMT was significantly greater in RA patients
treated only with synthetic DMARDs than in controls
(P= 0.035). In addition, the mean CCA-IMT was signifi-
cantly greater in RA patients treated only with synthetic
DMARDs than in RA patients treated with synthetic and
biologic DMARDs (P= 0.040). There was no significant dif-
ference between the mean CCA-IMT in RA patients trea-
ted with synthetic and biologic DMARDs and controls
(P= 0.997).
Discussion
The growing body of evidence of increased CV risk in RA
patients has led the rheumatology community to recog-
nize the importance of this in clinical practice and re-
search [510, 15, 16, 37]. Several CV scientific societies
have reported that CCA-IMT assessment should be
included in the routine assessment of CV risk [13, 37].
The criterion validity of CCA-IMT US measurement has
been established in histological studies [38]. The added
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value of CCA-IMT in CV risk assessment has been shown
also in RA patients [15, 16].
In our study we found a significantly greater CCA-IMT in
RA patients treated with synthetic DMARDs than in sex-
and age-matched controls who, in addition, did not show
differences in CV risk factors and co-morbidities as
compared with the above RA population. This result
was in accordance with those of previous studies that
compared RA patients receiving the above therapy with
controls [5, 17, 18, 2123]. Additionally, we found a sig-
nificantly greater CCA-IMT in RA patients treated only with
synthetic DMARDs than in RA patients treated with
TABLE 1 Demographic, clinical and laboratory data in RA patients who had received synthetic DMARDs, RA patients
who had received synthetic and biologic DMARDs and controls
Clinical and laboratory data
RA patients
treated with
synthetic
DMARDs
(n= 45)
RA patients
treated with
synthetic and
biologic
DMARDs
(n= 49)
Controls
(n= 94) P
Age, mean (S.D.), years 44.8 (9.2) 44.9 (8.5) 44.7 (8.7) 0.983
Sex, women, n (%) 39 (86.7) 44 (89.8) 83 (88.3) 0.895
BMI, mean (S.D.), kg/m2 25.9 (5.2) 24.3 (3.7) 24.3 (4.3) 0.099
WC, mean (S.D.), cm 87.2 (12.6) 82.8 (11.6) 82.2 (11.8) 0.067
SBP, mean (S.D.), mmHg 122.2 (15.8) 119.2 (15.6) 117.0 (14.9) 0.171
DBP, mean (S.D.), mmHg 76.7 (10.0) 73.8 (8.8) 75.0 (9.0) 0.322
Hypertension, n (%) 5 (11.1) 6 (12.2) 10 (10.6) 0.959
Diabetes mellitus, n (%) 2 (4.4) 0 (0.0) 1 (1.1) 0.193
Dyslipidaemia, n (%) 11 (24.4) 9 (18.4) 11 (11.7) 0.153
Renal insufficiency, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Obesity, n (%) 4 (8.9) 4 (8.2) 7 (7.4) 0.956
Hyperuricaemia, n (%) 1 (2.3) 0 (0.0) 0 (0.0) 0.202
Gout, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
PAD, n (%) 0 (0.0) 0 (0.0) 1 (1.1) 0.605
CAD, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
CBE, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
FH, n (%) 6 (13.3) 8 (16.7) 16 (17.2) 0.840
Smoking habit, n (%)
Current 10 (22) 20 (41) 19 (20) 0.036
Past 8 (18) 11 (22) 16 (17)
Never 27 (60) 18 (37) 59 (63)
RA duration, median (Q1Q3), months 48.0 (12.086.5) 84.0 (53.0164.0) NA <0.0005
SDMARDs duration, median (Q1Q3), months 10.0 (0.032.0) 40.5 (14.081.0) NA <0.0005
CSs duration, median (Q1Q3), months 21.0 (8.058.0) 55.0 (25.0146.3) NA <0.0005
BDMARDs duration, median (Q1Q3), months NA 32.0 (11.358.3) NA NA
DAS28, mean (S.D.), months 3.17 (1.39) 3.35 (1.36) NA 0.536
HAQ, median (Q1Q3) 0.37 (0.001.37) 0.88 (0.191.38) NA 0.029
RF, n (%) 32 (72.7) 34 (70.8) NA 0.840
ACPA, n (%) 24 (55.8) 35 (76.1) NA 0.043
ESR, mean (S.D.), mm/h 17.9 (14.5) 23.0 (20.9) NA 0.199
CRP, mean (S.D.), mg/l 4.6 (7.6) 5.4 (7.1) NA 0.619
WC: waist circumference; PAD: peripheral atherosclerotic arterial disease; CAD: coronary artery disease or events; CBE:
cerebrovascular events; FH: family history (i.e. first-grade relatives) of early (<50 years) CV events; SDMARDs: synthetic
DMARDs; BDMARDs: biologic DMARDs; NA: not applicable.
TABLE 2 Vascular assessment (CCA-IMT) values in RA patients and controls
Vascular assessment
RA patients treated with
synthetic DMARDs
(n= 45)
RA patients treated with
synthetic and biologic DMARDs
(n= 49)
Controls
(n= 94)
ANOVA
P
CCA-IMT, mean (S.D.), mm 591.4 (98.6) 558.8 (95.3) 562.1 (85.8) 0.023
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synthetic and biologic DMARDs despite significantly
longer disease duration, higher number of smokers and
worse HAQ in this latter group. However, the CCA-IMT
was comparable in the latter RA population and controls.
This cross-sectional finding is consistent with the results
of some longitudinal studies that have shown a signifi-
cantly greater increase in CCA-IMT in RA patients receiv-
ing synthetic DMARDs as compared with RA patients
receiving biologic therapy [2830]. It can also be argued
that the longer synthetic DMARDs and CS therapy might
have contributed to the smaller CCA-IMT in patients trea-
ted with synthetic and biologic therapy. However, the in-
fluence of these treatments on the CCA-IMT has not been
firmly elucidated [16, 39].
Some limitations in our study should be noted. The type
of study, being cross-sectional, limited any prediction or
causality assessment. In addition, the low prevalence of
CV co-morbidities did not allow us to analyse their relation
with the CCA-IMT in the studied populations.
In conclusion, our results suggest that radiofrequency-
based measurement of CCA-IMT was able to discriminate
between RA patients treated with synthetic DMARDs vs
RA patients treated with synthetic and biologic DMARDs,
and that biologic therapy may have a protective effect on
the increased carotid IMT and atherosclerotic process
widely described in the literature on RA patients. Further
longitudinal studies on the long-term effect of synthetic
and biologic treatment on carotid IMT are warranted.
Rheumatology key messages
. CCA-IMT was greater in RA patients on DMARDs
as compared with those on biologic therapy.
. Biologic therapy may have a protective effect on
the atherosclerotic process in RA patients.
. Implementation of carotid IMT in rheumatology
practice may provide additional value to RA
management.
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